CDMO: How to find a reliable partner
Every biopharmaceutical company reaches the same crossroads when selecting a contract development and manufacturing (CDMO) partner. The temptation is to optimize for the lowest quote or the shortest lead time, or both. But the most consequential question is rarely asked directly: which partner will actually carry your program from early-phase clinical through commercial launch without a single avoidable disruption?
At Richter BioLogics, nearly 40 years of serving the global pharmaceutical and biotechnology industry have taught us that several questions deserve a clear answer.
“Won’t a large, global CDMO give us more security than a specialist?”
Company size can be reassuring, but it is not the same as reliability. Larger providers often spread capacity across a broad range of modalities and a fairly large number of clients, which can mean your program competes for attention and expertise.
Richter BioLogics offers something better: deep, focused specialization in microbial manufacturing. Your program, whether it’s a protein, an antibody (VHH/nanobody, ScFv-fragment, pDNA, or a vaccine, benefits from teams whose expertise is concentrated, and from an organization small enough to remain genuinely responsive while mature enough to withstand any regulatory scrutiny.
Consistent quality outcomes require consistent people, processes, and leadership rather than reactive management. Our stability on all three fronts is a direct advantage to the programs we support.
“What does a quality mindset actually change in daily operations?”
Quality in CDMO manufacturing is not simply a matter of passing audits. The real measure is whether that rigor is embedded in day-to-day work: in how deviations are investigated, how processes are validated, and how knowledge is preserved across teams.
At Richter BioLogics, quality is an operating philosophy that runs through every function, and every client engagement. For your program, that means fewer surprises, more predictable timelines.
“Why does a CDMO’s regulatory record matter?”
Because a clean regulatory record signals several things about a prospective partner:
Process robustness: Systems that satisfy multiple regulatory bodies across multiple inspection cycles rest on sound scientific and procedural foundations.
Documentation integrity: Zero findings in an FDA inspection reflect a documentation culture that is both thorough and accurate.
Risk mitigation: Every regulatory finding creates downstream risk for timelines, submission dossiers, and commercial supply continuity. A strong inspection record reduces that risk materially.
Your partner’s regulatory credibility directly strengthens the integrity of your dossier. Beyond our recent FDA inspection with zero observations, our quality standards are continuously confirmed by the EMA, ANVISA, PMDA, MFDS, and others, among the most stringent regulatory environments in the world.
“Can a quality-first partner still move at the pace we need?”
Yes, and this is the central point. Quality is not a constraint on speed but it is the foundation that makes it possible. That continuity is reflected in several years of revenue growth at Richter BioLogics, sustained by maintaining the standards that keep clients engaged for the long term. The right partnership delivers both quality and pace, because one enables the other.
Let’s continue the conversation
If you are evaluating partners for your next protein, antibody, vaccine, or pDNA program, we welcome the discussion. Meet our team at CPhI Milan 2026, Hall 12, Booth F65 (#12F65) taking place October 6-8.
Contact us:
Richter BioLogics GmbH
Dr. Thilo Kamphausen, Director of Business Development – t.kamphausen@richterbiologics.eu
Dr. Kai Pohlmeyer, Managing Director – k.pohlmeyer@richterbiologics.eu
Learn more:
richterbiologics.eu
linkedin.com/company/richterbiologics
This article is sponsored by Richter BioLogics.
